DOCSLIB.ORG

Quest Diagnostics Prescription Drug Monitoring Reference Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quest Diagnostics Prescription Drug Monitoring Reference Guide Clinical Drug Monitoring Reference Guide Clinical Drug Monitoring Test List with Test Codes Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Cocaine Metabolite 92225 70248 16888 90082 16916 Naltrexone 93753 Amphetamines 92222 70245 16885 70209 16913 Eszopiclone 91251 Opiates 92230 18991 16891 70237* 16298* Amphetamines Fentanyl 36278 36279 36280 18996 16900 Oxycodone 92231 18992 16892 70238 16920 91590 91589 92484 92483 with Reflex d/l Isomers Gabapentin 70205 16904 Phencyclidine 92232 18993 16893 90083 16921 Antidepressants (urine) 94032 Heroin Metabolite 92226 90081 16911 90333 90329 Pregabalin 70208 16908 Antidepressants (serum) 94031 Marijuana Metabolite 92227 18989 16889 70233 16917 Propoxyphene 92233 18995 16894 70239 16922 Antipsychotics (urine) 94528 MDMA/MDA 92228 90078 16909 90334 90331 Synthetic Cannabinoids 93027 Antipsychotics (serum) 94529 Meperidine 70206 16905 Synthetic Stimulants 90322 Barbiturates 92223 70246 16886 70230 16912 Methadone Metabolite 92229 18990 16890 70234 16918 Tapentadol 90244 90243 Benzodiazepines 92224 70247 16887 70231 16914 Methamphetamine Tramadol 70207 16906 90319 Buprenorphine 16207 70249 16901 18998 16213 d/l Isomers Tricyclic Antidepressants 70204 16903 Buprenorphine 93093 93094 Methylphenidate 90247 90246 with Naloxone Zolpidem 91258 Mitragynine 39241 39240 Carisoprodol 18999 16902 *Includes oxycodone drug class Test Profiles Profile Name Base Profile Profile 1 Profile 2 Profile 3 Profile 4 Profile 5 Profile 6 Profile 7 Profile 8 and Test Codes 16260 16259 16457 92466 92450 92451 92458 92459 92467 92453 92461 16855 16854 16456 92468 92454 92462 90347 90348 92455 90318 92463 92456 92464 92457 92465 92489 92490 Drug Class P P,D,M P,D P P,D,M P,D,M P,D P,D P P,D,M P,D P P,D,M P,D P P,D,M P,D P P,D,M P,D,M P,D P,D P,D,M P,D P,D,M P,D P,D,M P,D Alcohol Metabolites/ETG ALC ALC ALC ALC ALC ALC Amphetamines AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP Amphetamines d/l Isomers ADL ADL ADL ADL Barbiturates BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR BAR Benzodiazepines BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN BEN Buprenorphine BUP BUP Cocaine Metabolite COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC COC Heroin Metabolite HER HER HER HER HER HER Marijuana Metabolite MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MAR MDMA/MDA MDM MDM Methadone Metabolite MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH MTH Opiates OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI OPI Oxycodone OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY OXY Phencyclidine PCP PCP PCP PCP PCP PCP PCP PCP PCP PCP P = Presumptive D = Definitive M = medMATCH® Page 2 Clinical Drug Monitoring Test Profiles Profile 1 with Amphetamines Base Profile Profile 1 d/l Isomers Profile 2 16260 (P), 16259 (P,D,M), 16457 (P,D) 92466 (P), 92450 (P,D,M), 92458 (P,D) 92451 (P,D,M), 92459 (P,D) 92467 (P), 92453 (P,D,M), 92461 (P,D) Benzodiazepines Amphetamines Amphetamines with Reflex d/l Isomers Methadone Metabolite Cocaine Metabolite Barbiturates Barbiturates Opiates Opiates Benzodiazepines Benzodiazepines Oxycodone Oxycodone Cocaine Metabolite Cocaine Metabolite Marijuana Metabolite Marijuana Metabolite Methadone Metabolite Methadone Metabolite Opiates Opiates Oxycodone Oxycodone Phencyclidine Phencyclidine Profile 5 with Amphetamines Profile 3 Profile 4 Profile 5 d/l Isomers 16855 (P), 16854 (P,D,M), 16456 (P,D) 92468 (P), 92454 (P,D,M), 92462 (P,D) 90347 (P), 90348 (P,D,M), 90318 (P,D) 92455 (P,D,M), 92463 (P,D) Amphetamines Amphetamines Amphetamines Amphetamines with Reflex d/l Isomers Benzodiazepines Barbiturates Barbiturates Barbiturates Cocaine Metabolite Benzodiazepines Benzodiazepines Benzodiazepines Marijuana Metabolite Cocaine Metabolite Cocaine Metabolite Cocaine Metabolite Opiates Methadone Metabolite Marijuana Metabolite Marijuana Metabolite Oxycodone Opiates Methadone Metabolite Methadone Metabolite Oxycodone Opiates Opiates Phencyclidine Oxycodone Oxycodone Profile 6 Profile 7 Profile 8 92456 (P,D,M), 92464 (P,D) 92457 (P,D,M), 92465 (P,D) 92489 (P,D,M), 92490 (P,D) For healthcare professionals Alcohol Metabolites/EtG Alcohol Metabolites/EtG Alcohol Metabolites/EtG Amphetamines Amphetamines Amphetamines seeking assistance with Barbiturates Barbiturates Benzodiazepines Benzodiazepines Benzodiazepines Buprenorphine interpreting results, please Cocaine Metabolite Cocaine Metabolite Cocaine Metabolite contact a Quest Diagnostics Heroin Metabolite Heroin Metabolite Heroin Metabolite Marijuana Metabolite Marijuana Metabolite Marijuana Metabolite Toxicology Specialist Methadone Metabolite Methadone Metabolite MDMA/MDA Opiates Opiates Opiates at 1.877.40.R X TOX Oxycodone Oxycodone Oxycodone (1.877.407.9869), Phencyclidine M–F 8:00 AM to P = Presumptive D = Definitive M = medMATCH® 10:00 PM ET. Page 3 Clinical Drug Monitoring Reference Guide Presumptive Definitive Reportable Drug Additional Reportable Drug/ Drug/Drug Class Examples of Generic/Trade/Street Name Urine Detection Timea Cutoff (ng/mL) Cutoff (ng/mL) or Metabolite Metabolitea 500 Ethyl Glucuronide (EtG) Ethyl Sulfate (EtS) Alcohol Metabolites 500 Up to 80 Hours 100 Ethyl Sulfate (EtS) Ethyl Glucuronide (EtG) Amphetamine Amphetamine — Adderall®, Dexedrine®, Dextrostat®, Vyvanse® Amphetamines 500 250 Methamphetamine — Desoxyn® 1–3 Days Methamphetamine Amphetamine Benzphetamine — Didrex® Amphetamine Amphetamine — Adderall®, Dexedrine®, Dextrostat®, Vyvanse® 250 Methamphetamine — Desoxyn® Methamphetamine Amphetamine Amphetamines Benzphetamine metabolite — Didrex® with Reflex 500 d-Methamphetamine — Desoxyn® 1–3 Days Methamphetamine d-Methamphetamine d/l Isomers Benzphetamine d-metabolite — Didrex® Selegiline l-metabolite — Eldepryl® l-Methamphetamine l-Methamphetamine —nasal inhaler Amitriptyline Nortriptyline Amitriptyline — Elavil®, Endep® Amoxapine Amoxapine — Asendin® Citalopram/Escitalopram Desmethylcitalopram Citalopram/Escitalopram — Celexa® (citalopram), Lexapro® Desmethylcitalopram (escitalopram) Clomipramine Desmethylclomipramine Clomipramine — Anafranil® Desmethylclomipramine Imipramine Imipramine — Tofranil® Desipramine Desipramine — Norpramin® Doxepin Desmethyldoxepin Antidepressantsc 10 10 Doxepin — Adapin® , Sinequan® 1–3 Days Desmethyldoxepin Duloxetine Duloxetine — Cymbalta® Fluoxetine Norfluoxetine Fluoxetine — Prozac® Norfluoxetine Fluvoxamine Norfluvoxamine Fluvoxamine — Luvox® Norfluvoxamine Hydroxybupropion Hydroxybupropion — Aplenzin® (bupropion) Imipramine Desipramine Imipramine — Tofranil® Maprotiline Maprotiline — Ludiomil® a Depends upon drug usage patterns, drug/drug metabolite elimination, and test cutoff Note: Unless otherwise specified, the presumptive method of analysis is immunoassay. b Naloxone is reported when ordered c Presumptive analysis uses mass spectrometry method of analysis Page 4 Clinical Drug Monitoring Reference Guide Presumptive Definitive Reportable Drug Additional Reportable Drug/ Drug/Drug Class Examples of Generic/Trade/Street Name Urine Detection Timea Cutoff (ng/mL) Cutoff (ng/mL) or Metabolite Metabolitea Mirtazapine Mirtazapine — Remeron® Amitriptyline Amitriptyline — Elavil®, Endep® Nortriptyline Nortriptyline — Aventyl® 10 10 Paroxetine Paroxetine — Paxil®, Seroxat® Protriptyline Protriptyline — Vivactil® Sertraline Norsertraline Sertraline — Zoloft® 50 50 Norsertraline Antidepressantsc 1–3 Days Trazodone 1-(3-Chlorophenyl)piperazine Trazodone — Desyrel® 1-(3-Chlorophenyl)piperazine Trimipramine Trimipramine — Surmontil® 10 10 Venlafaxine O-desmethylvenlafaxine Venlafaxine — Effexor® XR (venlafaxine), Khedezla O-desmethylvenlafaxine (desvenlafaxine) Vilazodone Vilazodone — Viibryd® Vortioxetine Vortioxetine — Trintellix® 2 Aripiprazole Dehydroxyaripiprazole 2 Aripiprazole — Abilify® 10 Dehydroxyaripiprazole 5 5 Brexpiprazole Brexpiprazole — Rexulti® 5 5 Cariprazine Cariprazine — Vraylar® Chlorpromazine 7-OH-chlorpromazine 10 10 Chlorpromazine — Largactil, Thorazine® 7-OH-chlorpromazine Clozapine Norclozapine 25 25 Clozapine — Clozaril® Norclozapine Fluphenazine 7-OH-fluphenazine Antipsychoticsc 5 5 Fluphenazine — Prolixin®, Modecate 1–3 Days 7-OH-fluphenazine 1 1 Haloperidol Haloperidol — Haldol® Loxapine 8-hydroxyloxapine 5 5 Loxapine — Loxapac, Loxitane® 8-hydroxyloxapine 5 5 Lurasidone Lurasidone — Latuda® 10 10 Mesoridazine Mesoridazine — Serentil® 5 5 Molindone Molindone — Moban® Olanzapine Desmethylolanzapine 2.5 2.5 Olanzapine — Zyprexa® Desmethylolanzapine a Depends upon drug usage patterns, drug/drug metabolite elimination, and test cutoff Note: Unless otherwise specified, the presumptive method of analysis is immunoassay. b Naloxone is reported when ordered c Presumptive analysis uses mass spectrometry method of analysis Page 5 Clinical Drug Monitoring Reference Guide Presumptive Definitive Reportable Drug Additional Reportable Drug/ Drug/Drug Class Examples of Generic/Trade/Street Name Urine Detection Timea Cutoff (ng/mL) Cutoff (ng/mL) or Metabolite Metabolitea Quetiapine Norquetiapine 10 10 Quetiapine — Seroquel® Norquetiapine Risperidone OH-risperidone 5 5 Risperidone — Risperdal® OH-risperidone Antipsychotics 1–3 Days 50 50 Thioridazine Thioridazine — Mellaril®, Melleril Thiothixene Thiothixene — Navane®
Load more

Recommended publications
  • Highlights of This Issue
    THURSDAY, OCTOBER 4, 1973 WASHINGTON, D.C. HIGHLIGHTS OF THIS ISSUE This listing does not affect the legal status of any document published in this issue. Detailed table of contents appears inside. ECONOMIC STABILIZATION— CLC Phase IV pay and price regulations for certain reg­ istered, practical, and trained nurses (2 documents); effective 10—1—73....................... ........................ 27528, 27529 CLC allows Phase IV price increases for rubber tire and tube products; effective 10—8—73............................. ....... 27528 October 4, 1973— -Pages 27501-27574 METHAQUALONE— Justice Department classifies as Schedule II controlled substance; effective 10—4—73 27516 ARTISTS' PAINTS AND SUPPLIES— Consumer Product Safety Commission exempts from lead content restric­ tions; effective 12—3—73...-......... ........................................ 27514 DEFENSE CONTRACTS— Cost Amounting Standards Board extends disclosure statement filing requirements; effective 4— 1—74............................. ....................................... 27507 PUBLIC ASSISTANCE— HEW proposal on determin­ ing paternity of children receiving aid; comments by 1 1 -5 -7 3 ............................................ -. ............ : ........ 27530 SUGAR— USDA declares and reprorates 1973 quota deficits for Hawaii and Peru................... .................... ........................ 27509 USDA requires no proportionate shares for 1974 sugarbeet crop..--....................... ..............."...................... — 27510 PEANUTS— USDA proposes 1974
    [Show full text]
  • Drug Detection Time Window Chart
    Chesapeake Toxicology Resources Drug Detection Windows Updated as of December, 15th 2014 The length of time that the presence of drugs of abuse in the body can be detected is an important factor in drug screening. The chart below outlines approximate duration times. When interpreting the duration for the presence of drugs of abuse in the body, you must take into consideration variables including the body's metabolism, the subject's physical condition, overall body fluid balance, state of hydration and frequency of usage. Amphetamines Drug Name Metabolite Detection Window Prescription Names Amphetamine 3-5 Days Adderall, Adderall XR, Dexedrine, Spansule, DextroStat MDA 2-5 Days Tenamfetamine MDMA MDA 1-3 Days Adam, Ecstacy Methamphetamine Amphetamine 3-5 Days Desoxyn, Desoxyn Gradument Anti-epileptics Drug Name Metabolite Detection Window Prescription Names Gabapentin 1-5 Days Neurontin, Nupentin, Fanatrex, Gabarone, Gralise Pregablin 1-4 Days Lyrica CHESAPEAKE TOXICOLOGY RESOURCES- DRUG DETECTION TIMETABLE !1 Barbiturates Drug Name Metabolite Detection Window Prescription Names Amobarbital 2-10 Days Amytal, Amylobarbiton, Tuinal Butalbital 4-6 Days Axocet, Axotal, Bucet, Bupap, Butex Forte, Cephadyn, Dolgic, Esgic, Esgic-Plus, Fioricet, Fiorinal, Fiormor, Fiortal, Fortabs, Laniroif, Margesic, Marten-Tab, Medigesic, Phrenilin, Phrenilin Forte, Repan, Sedapap, Tencon, Triad Pentobarbital 2-10 Days Euthasol, Nembutal , Nembutal Sodium, Pentasol Phenobarbital Up to 16 days Antrocol, Barbidonna, Barbita, Bellacane, Bellatal, Bellergal-S, Chardonna-2,
    [Show full text]
  • Treatment Episode Data Set (TEDS) 2003 - 2013
    Treatment Episode Data Set (TEDS) 2003 - 2013 National Admissions to Substance Abuse Treatment Services DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration ACKNOWLEDGMENTS This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), by Synectics for Management Decisions, Inc. (Synectics), Arlington, Virginia. Work by Synectics was performed under Task Order HHSS283200700048I/HHSS28342001T, Reference No. 283-07-4803 (Cathie Alderks, Task Order Officer). PUBLIC DOMAIN NOTICE All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, U.S. Department of Health and Human Services. RECOMMENDED CITATION Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. ELECTRONIC ACCESS AND COPIES OF PUBLICATION This publication may be downloaded or ordered at store.samhsa.gov. Or call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). ORIGINATING OFFICE Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Room 2-1084 Rockville, Maryland 20857 December 2015 ii TABLE OF CONTENTS List of Tables ...................................................................................................................................v List of Figures ..............................................................................................................................
    [Show full text]
  • A Comparison of Drug Use in Driver Fatalities and Similarly Exposed Drivers
    DOT HS-802 488 A COMPARISON OF DRUG USE IN DRIVER FATALITIES AND SIMILARLY EXPOSED DRIVERS Contract No. DOT-HS-4-00941 July 1977 Final Report PREPARED FOR: U.S. DEPARTMENT OF TRANSPORTATION NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION WASHINGTON, D.C. 20590 Document is available to the public through the National Technical Information Service, Springfield, Virginia 22161 This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchange. The United States Govern­ ment assumes no liability for its contents or use thereof. Technical Report Documentation Page 1. Report No. 2. Goeemm.nt Accession No. 3. Recipient's Catalog No. DOT HS-802 488 -^. 1. Title and Subtitle 5. Report Date July 1977 A COMPARISON OF DRU^ USE IN DRIVER FATALITIES 6. Performing Organization Code AND SIMILARLY EXPOSED DRIVERS . B. Performing Organization Report No. 7. Authorrs) Robert R. Blackburn, Edward J. Woodhouse 3963-D 9. Performing Organization Name and Address 10. Worb Unit No. (TRAIS) Midwest Research Institute I). Contract at Grant No. 425 Volker Boulevard DOT-HS-4-00941 Kansas City, Missouri 64110 13. Type of Report and Period Covered 12. Sponsoring Agency Name and Address 28 June 1974-25 March 1977 i U.S. Department of Transportation National Highway Traffic Safety Administration Final Report Washington, D.C. 20590 14. Sponsoring Agency Code 15. supplementary Notes 16. Abstract Crash information, urine, blood and bile samples from 900 fatally injured drivers were collected by medical examiners in 22 areas of the country. Ran­ domly selected living drivers were interviewed at times and places of recent fatal crashes in Dallas, Texas, and Memphis, Tennessee and breath, urine, and blood samples were obtained.
    [Show full text]
  • The Epidemiology of Benzodiazepine Misuse a Systematic Review
    Drug and Alcohol Dependence 200 (2019) 95–114 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep Review The epidemiology of benzodiazepine misuse: A systematic review T ⁎ Victoria R. Votawa, , Rachel Geyerb, Maya M. Rieselbachc, R. Kathryn McHughb,d a Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque, NM, USA b Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA, USA c Department of Psychiatry, McLean Hospital, 115 Mill Street, Belmont, MA, USA d Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, USA ARTICLE INFO ABSTRACT Keywords: Background: Benzodiazepine misuse is a growing public health problem, with increases in benzodiazepine-re- Benzodiazepines lated overdose deaths and emergency room visits in recent years. However, relatively little attention has been Sedatives paid to this emergent problem. We systematically reviewed epidemiological studies on benzodiazepine misuse to Tranquilizers identify key findings, limitations, and future directions for research. Prescription drug misuse Methods: PubMed and PsychINFO databases were searched through February 2019 for peer-reviewed publica- Nonmedical prescription drug use tions on benzodiazepine misuse (e.g., use without a prescription; at a higher frequency or dose than prescribed). Eligibility criteria included human studies that focused on the prevalence, trends, correlates, motives, patterns, sources, and consequences of benzodiazepine misuse. Results: The search identified 1970 publications, and 351 articles were eligible for data extraction and inclusion. In 2017, benzodiazepines and other tranquilizers were the third most commonly misused illicit or prescription drug in the U.S. (approximately 2.2% of the population).
    [Show full text]
  • DRUGS of ABUSE I 2011 EDITION: a DEA Resource Guide of Actual Abuse of a Substance Is Indicative That a Drug Has a Schedule I Potential for Abuse
    U.S. Department of Justice DrUg enforcement AdminiStration WWW.DEA.GOV Drugs of2011 Abuse Edition A DEA REsouRcE GuiDE II. Controlled Substances Act coNtRolliNG DRuGs oR othER The Assistant Secretary, by authority of the Secretary, compiles substANcEs thRouGh FoRmAl the information and transmits back to the DEA: a medical and schEDuliNG scientific evaluation regarding the drug or other substance, a recommendation as to whether the drug should be controlled, The Controlled Substances Act (CSA) places all substances and in what schedule it should be placed. which were in some manner regulated under existing federal The medical and scientific evaluations are binding on the DEA law into one of five schedules. This placement is based upon with respect to scientific and medical matters and form a part the substance’s medical use, potential for abuse, and safety or of the scheduling decision. dependence liability. The Act also provides a mechanism for substances to be controlled (added to or transferred between Once the DEA has received the scientific and medical schedules) or decontrolled (removed from control). The evaluation from HHS, the Administrator will evaluate all available procedure for these actions is found in Section 201 of the data and make a final decision whether to propose that a drug Act (21 U.S.C. § 811). or other substance should be removed or controlled and into which schedule it should be placed. Proceedings to add, delete, or change the schedule of a drug If a drug does not have a potential for abuse, it cannot be or other substance may be initiated by the Drug Enforcement controlled.
    [Show full text]
  • Docobent Mune
    DOCOBENT MUNE ED 099 721 88 CO 009 311 Drug Information and Attitude Development: Interim Evaluation Report, August 1, 1972 to July 31, 1973, TISTITUTION Ferguson-Florissant School District, Ferguson, Bo. SPONS AGENCY Bureau of Elementary and Secondary Education (DBEV/OE), Washington, D.C. BUREAU NO 25-71-04-2 PUB DATE Sep 73 NOTE 284p. EDRS PRICE BF-80.75 BC-$13.80 PLUS POSTAGE DESCRIPTORS *Adolescents; Community Involvement; *Drug Education; Elementary Secondary Education; Family Involvement; *Inservice Education; *Program Descriptions; Research Projects IDENTIFIERS *Elementary Secondary Education Act Title III; ESEA Title III ABSTRACT This interim evaluation reports on the progress of an extensive drug education program in a St. Louis, Missouri school district. Designed to meet seven overall objectives, the project calls for comparisons between experimental and control groups at the elementary and secondary level. Far-reaching activities including staff orientation and training, curriculum developmentand implementation, staff and curriculum support, and parental involvement are discussed and evaluated in terms of their benefit to the overall objectives. A summary of all disseminationactivities is included, as are copies of all materials circulated by the project. Appendixes to the report include statistical analyses from both the student evaluation instruments and those utilized with the teacher training program. (Author/PC) DRUG INFORMATION 1 e n d ATTITUDE DEVELOPMENT U S DEPARTMENT OF ME Attic f DUCAT SON WELFARE NATIONAL INSTITUTE Of foutATioal 4415toocumfNT .445 SEENREPRO DuCED EYACTi Y AS RI. CEIV4 0 6 ROM 'He PE 66S066 OR 000AAtt A V 'ON GRsGIN AT try&T POuvts06 tiff ItS OR 04616410RIS SUMO DO NOT Alf cissAu61y REPEL SENT Off tCtAt tyAt0Aatil INSTITUTE Of Project Submitted Under EDUCAt Mfg Kiss 110,6OR POI Y Title III, ESEA Public Act 89-10 INTERIM EVALUATION REPORT Project # 25-71-04-2 Augrst 1, 1972 to July 31, 1973 RECrril=o The Ferguson-Florissant School District St.
    [Show full text]
  • Pavlovian Conditioning and Heroin Overdose: Reports by Overdose Victims
    Bulletin of the Psychonomic Society 1984, 22 (5), 428-430 Pavlovian conditioning and heroin overdose: Reports by overdose victims SHEPARD SIEGEL McMaster University, Hamilton, Ontario, Canada A Pavlovian conditioning model of tolerance emphasizes the contribution of an association between predrug cues and the systemic effects of the drug to tolerance. In agreement with the model, results of a recent animal experiment indicate that the lethal effect of heroin, in drug­ experienced rats, is influenced by the cues associated with its administration. To assess the ap­ plicability of these findings to instances of heroin overdose in humans, overdose survivors were questioned about the circumstances of their overdose. These retrospective reports by human victims are congenial with these animal data, and suggest that the conditioning model may be relevant to some instancesofoverdosedeathamongheroin addicts. Each year, approximately 1% of heroin addicts die, result from a failure of tolerance; that is, the opiate mostly from an acute reaction to an intravenously addict, who can usually tolerate extraordinarily high administered heroin solution-eo-called "overdose" doses, is not tolerant on the occasion of the overdose death (Maurer & Vogel, 1973 , p. 101). The mechanisms (Siegel, Hinson, Krank , & McCully, 1982). Such a failure of many of these deaths are unclear. Some result from a of tolerance is explicable on the basis of a model of pharmacological overdose (e.g., Huber, 1974), but many toler ance emphasizing Pavlovian conditioning principles victims die following a dose that would not be expected (reviewed by Siegel, 1983). The model is based on to be fatal for these drug-experienced, and presumably Pavlov's (1927, p.
    [Show full text]
  • Hs172a R01/10 1 Session Ix Central Nervous System
    SESSION IX CENTRAL NERVOUS SYSTEM DEPRESSANTS HS172A R01/10 1 SESSION IX CENTRAL NERVOUS SYSTEM DEPRESSANTS Upon successfully completing this session the student will be able to: o Explain a brief history of the CNS Depressant category of drugs. o Identify common drug names and terms associated with this category. o Identify common methods of administration for this category. o Describe the symptoms, observable signs and other effects associated with this category. o Describe the typical time parameters, i.e. onset and duration of effects, associated with this category. o List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. o Correctly answer the "topics for study" questions at the end of this session. HS172A R01/10 2 A. Overview of CNS Depressants Central Nervous System Depressants slow down the operations of the brain. They first affect those areas of the brain that control a person's conscious, voluntary actions. As dosage increases, depressants begin to affect the parts of the brain controlling the body's automatic, unconscious processes, such as heartbeat and respiration. Alcohol is the model for the CNS Depressant category of drugs. Alcohol is the most familiar, and most widely abused, depressant. With some exceptions, all depressants affect people in much the same way as does alcohol. Some major subcategories of CNS Depressants other than alcohol include: • Barbiturates (Derivatives of Barbiturate Acid) • Non-Barbiturates (Synthetic compounds with a variety of chemical structures) • Anti-Anxiety Tranquilizers (Frequently prescribed and frequently abused) • Anti-Depressants (It may seem to be a contradiction in terms to call a subcategory of Depressants the Anti-Depressants; but in this case, we simply mean that these drugs are prescribed to combat psychological depression.
    [Show full text]
  • Oregon Health & Science University
    Oregon Health & Science University Department of Pathology Center for Health and Healing Lab Interpretive Summary of Cross-Reactivity of Substances, Duration of Drug Detectability and Adulteration Testing/Specimen Validity Testing in Drugs of Abuse Screening Methods CROSS REACTIVITY Cross-reactivity of structurally similar substances is a problem associated with immunoassay methodologies, resulting in false positive or negative results. Screening technologies are predominantly immunoassay techniques which may prove high sensitivity but are of limited specificity. Manufacturers will test for common potential interfering substances and list these on the package insert, however it is not possible to test every compound. Also some compounds ingested in therapeutic dosage may not cross-react, however when abused in “mega” doses may significantly influence urine immunoassay results. Listed below are potential reactants and cross-reactants with most immunoassay methodologies COMPOUND (Generic Name) COMPOUND (Trade Name) RESULTS/CROSS REACTANTS Acetaminophen (see also Aceta, Acephen, Apacet, Non-reactive Paracetamol) Dapacen, Feverall, Tylenol, Excedrin (combination), Panadol, Tempra Acetaminophen with Codeine (see Tylenol 3, Tylenol with codeine Positive for Opiates (OPI) Potential also Paracetamol with codeine) cross reactants: Dihydrocodeine 6-Acetylmorphine Positive for Opiates (OPI) Acetone Non- reactive Allobarbital Positive for Barbiturates (BAR) Alphenol No known trade names Positive for Barbiturates (BAR) Alprazolam Xanax Positive for
    [Show full text]
  • Module 6 Drugs and Substance Use
    Module 6 Drugs and Substance Use Module 6: Drugs and Substance Use FLOW CHART Content Flow at A Glance Module 6: Drugs and Substance Use Subject/topic/activity Objective Page No. Introduction to drugs and To give a background of the 6-2 to 6-4 injecting drug use. drug use in the Asian a nd Pacific Region and to establish the link with HIV/AIDS. Some critical concepts To explore the answers to some 6-5 to 6-18 basic questions on substance use. Exercise – Exploring To develop a common 6-19 substance use. understanding of substance use. Exercise – Myths and facts To provide correct information 6-20 to about drugs. about drugs and drug use. 6-23 Exercise – I am choking! To raise awareness on smoking 6-24 to and tobacco use. 6-27 Exercise – I feel woozy! To demonstrate the affect of 6-28 to alcohol use. 6-30 Exercise – Scoring and To understand the reasons for 6-31 to ranking the reasons. drug use among young people. 6-34 Case Study – Story of Woo. To raise awareness on the 6-35 to consequences of drug use. 6-36 Role-plays – Resolving an To make and practise strategies 6-37 to issue. for dealing with risk situations. 6-38 Exercise – No, thank you. To practise negotiation and 6-39 to refusal skills. 6-41 6-1 Module 6: Drugs and Substance Use Module 6 Drugs and Substance Use “Live neither in the entanglem ents of outer things, nor in inner feelings of emptiness”. Sengstan I Introduction he consumption and injecting of illicit drugs is increasing around the world, involving perhaps 20 million people in more than 120 countries.
    [Show full text]
  • Narcotics Dangerous Drugs
    If you have issues viewing or accessing this file contact us at NCJRS.gov. Ir I - This microfiche was produced from documents received for inclusion in the NCJRS data base. Since NCJRS cannot exercise control ovcr the physical condition of the documents submitted, the individual frame quality will vary. The resolution chart on this frame may be used to evaluate the document quality. 1.0 1.1 REFERENCE BOOK -- -- 111111.8 \\\\\1.25 111111.4 \\\\\1.6 NARCOTICS AND MICROCOPY RESOLUTION TEST CHART NATIONAL" BUREAU '.F STANDARDS-\963-A DANGEROUS DRUGS Microfilming procedures used to create this fiche comply with i ! the standards set forth in 41CFR 101·11.504 " Compiled by Points of view or opinions stated in this document an I those of the 3uthorlsj and do not represent the official GLENDALE CRIME LABORATORY position or policies of the U.S. Department o,f Justice. 5909 N. Milwaukee River Parkway Glendale, Wisconsin 53209 U.S. DEPARTMENT OF JUSTICE LAW ENFORCEMENT ASSISTANCE ADMINISTRATION" o NATIONAL CRiMINAL JUSTICE REFERENCE SERVICE WASHINGTON, D.C. 20531 ·00 Q a PRICE $'1 12/9/ 75 .,',' J INTRODUCTION This compilation has been taken from many sources primarily for '- use by participants in seminars and workshops on "Narcotics and Dangerous Drugs" conducted by the Glendale Crime Laboratory and for users of the Glendale Crime Laboratory Automated Teaching System programs on "Narcotics and Dangerous Drugs." This com­ pilation is not meant to be all inclusive. Your comments, criticisms and notation of errors would 'De ap­ preciated. Materials for inclusion in future revision would be ap­ preciated.
    [Show full text]